Loading...

NEXTGEN LIQUICORE 118 GENE PANEL ( MSI)

image not found

NABL Cap Accredited 
The NextGen LiquiCore 118 Gene Panel (MSI) at Metropolis Healthcare is a comprehensive liquid biopsy–based genomic test designed to detect mutations across 118 cancer-related genes along with microsatellite instability (MSI) status. This panel provides critical molecular insights for diagnosing cancers, selecting targeted therapies, and assessing immunotherapy eligibility. Metropolis Healthcare uses advanced Next-Generation Sequencing with ultra-deep coverage to ensure accurate detection of tumor-derived genetic alterations from blood. It is ideal for patients requiring minimally invasive genomic profiling or monitoring of cancer progression.

  • 17 Crores+ Samples Processed
  • World Class Technology Labs
  • 25+ Years of Trust & Experience
  • Free Home Collection

Price: Rs. 60,000.00

Sample Type: Maternal Blood

Fasting Not Required


Notes:N8190

Frequently Asked Questions (FAQ's):

What does the NextGen LiquiCore 118 Gene Panel (MSI) at Metropolis Healthcare include?
It analyzes 118 cancer-associated genes and assesses MSI status to guide targeted therapy and immunotherapy decisions.

How does Metropolis Healthcare perform this liquid biopsy test?
Metropolis Healthcare uses high-depth NGS to detect tumor-derived DNA mutations from a blood sample with excellent precision.

Who should consider this LiquiCore 118 Gene Panel at Metropolis Healthcare?
Individuals with solid tumors, those unable to undergo tissue biopsy, or patients needing molecular profiling for advanced treatments should take this test.

Is fasting required for the LiquiCore liquid biopsy at Metropolis Healthcare?
No, fasting is not required; a simple blood draw is sufficient.

How long do results take at Metropolis Healthcare?
Results typically take 2–3 weeks due to in-depth sequencing and complex genomic analysis.

Can this test at Metropolis Healthcare guide cancer treatment?
Yes, it helps identify actionable mutations and MSI status, which are crucial for selecting targeted therapies and immunotherapies.

How accurate is this liquid biopsy panel at Metropolis Healthcare?
Metropolis Healthcare ensures high accuracy with ultra-deep sequencing, validated workflows, and expert molecular interpretation.

Can this test help monitor cancer progression at Metropolis Healthcare?
Yes, it can be used for ongoing monitoring of tumor mutations and treatment response using a non-invasive blood sample.

OUR corporates PARTNER

Feedback

Patient's Testimonials

Trusted by Thousands

OUR Accreditations

OUR Lab